Camidanlumab Biosimilar – Anti-IL2RA, CD25 mAb – Research Grade

Description of Camidanlumab Biosimilar - Anti-IL2RA, CD25 mAb - Research Grade

Introduction

Camidanlumab Biosimilar, also known as Anti-IL2RA or CD25 mAb, is a monoclonal antibody that targets the interleukin-2 receptor alpha (IL2RA) protein. This protein is found on the surface of activated T cells and is involved in the regulation of immune responses. Camidanlumab Biosimilar is a research grade antibody that has shown promising results in preclinical studies and is currently being evaluated for its potential therapeutic applications.

Structure of Camidanlumab Biosimilar

Camidanlumab Biosimilar is a recombinant humanized IgG1 monoclonal antibody. It is composed of two heavy chains and two light chains, each containing a variable and constant region. The variable regions of the antibody are responsible for binding to the IL2RA protein, while the constant regions provide stability and effector functions.

The antibody has a molecular weight of approximately 150 kDa and a half-life of around 21 days in humans. It is produced using recombinant DNA technology, where the gene for the antibody is inserted into a host cell, such as Chinese hamster ovary (CHO) cells, to produce large quantities of the antibody.

Mechanism of Action

Camidanlumab Biosimilar works by binding to the IL2RA protein on the surface of activated T cells. This prevents the binding of interleukin-2 (IL-2), a cytokine that is essential for the activation and proliferation of T cells. By blocking the IL-2 receptor, Camidanlumab Biosimilar inhibits T cell activation and reduces the production of pro-inflammatory cytokines, leading to a dampening of the immune response.

Additionally, Camidanlumab Biosimilar also has an Fc region that can interact with other immune cells, such as natural killer cells and macrophages, to induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This further enhances the antibody’s ability to target and eliminate activated T cells.

Research Applications

Camidanlumab Biosimilar has been extensively studied in preclinical models and has shown promising results in various research applications. Some of the key areas of research where this antibody has been used include:

Autoimmune Diseases Camidanlumab Biosimilar has been investigated as a potential treatment for autoimmune diseases, such as multiple sclerosis (MS), rheumatoid arthritis (RA), and psoriasis. These diseases are characterized by an overactive immune response, and the antibody’s ability to inhibit T cell activation makes it a promising candidate for these conditions.

In preclinical studies, Camidanlumab Biosimilar has been shown to reduce disease severity and improve symptoms in animal models of autoimmune diseases. It has also shown a favorable safety profile, making it a potential alternative to current treatments that often have significant side effects.

Organ Transplantation

Organ transplantation is often accompanied by immune rejection, where the body’s immune system attacks the transplanted organ. Camidanlumab Biosimilar has been investigated as a potential therapy to prevent organ rejection by inhibiting T cell activation and reducing the risk of immune rejection.

In preclinical studies, Camidanlumab Biosimilar has been shown to prolong the survival of transplanted organs and improve transplant outcomes. It is currently being evaluated in clinical trials for its potential use in organ transplantation.

Cancer Immunotherapy

Camidanlumab Biosimilar has also been studied as a potential therapy for cancer. By targeting activated T cells, the antibody can potentially inhibit the growth and spread of cancer cells, as well as enhance the body’s immune response against cancer.

In preclinical studies, Camidanlumab Biosimilar has shown promising results in various types of cancer, including lymphoma,